Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952771 | 0.84 | GRM5 (0.41) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952680 | 0.81 | GRM5 (0.46) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL3644247 | 0.81 | GRM5 (0.71) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952922 | 0.80 | GRM5 (0.63) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952801 | 0.77 | GRM5 (0.67) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952770 | 0.77 | GRM5 (0.46) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952766 | 0.76 | GRM5 (0.63) | GRM5CYP1A2CYP3A4 | |
| SCHEMBL13952803 | 0.75 | GRM5 (0.44) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL13952856 | 0.75 | ABHD6 (0.48) | GRM5CYP1A2MGLL | |
| SCHEMBL15051069 | 0.75 | GPR119 (0.53) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | GRM5 1/4885CYP1A2 3224/4885CYP3A4 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.